Last updated: July 27, 2025
Overview of NDC 51407-0486
The National Drug Code (NDC) 51407-0486 corresponds to [Product Name: Remdesivir (Veklury)], a broad-spectrum antiviral medication developed to treat viral infections, notably COVID-19. Approved by the FDA for specific conditions, Remdesivir saw rapid deployment during the pandemic, creating a unique market dynamic characterized by urgent demand, regulatory adaptations, and evolving pricing models.
Market Landscape and Therapeutic Positioning
Historical Context and Market Adoption
Initially authorized for emergency use in late 2020, Remdesivir (Veklury) gained prominence as one of the first antivirals targeting SARS-CoV-2. Its role was solidified through subsequent FDA approvals and inclusion in hospital treatment protocols globally. The drug's market uptake was driven primarily by emergency authorizations and shifting treatment guidelines favoring early antiviral intervention.
Post-pandemic, its utilization has transitioned chiefly into hospital settings for specific COVID-19 cases, with a diminished but steady demand as the pandemic subsides. The drug’s indication in other viral infections remains limited, constraining market expansion opportunities outside COVID-19.
Manufacturing & Supply Chain Considerations
Gilead Sciences Inc. manufactures Veklury, ensuring high-quality standards amid the pandemic's global supply demands. However, manufacturing constraints and supply chain disruptions influenced market availability and pricing trends during peak demand periods.
Competitive Landscape
Remdesivir faces competition from monoclonal antibodies, corticosteroids like dexamethasone, and emerging oral antivirals (e.g., Paxlovid). Although no direct substitutes fully replicate its IV administration profile, the therapeutic landscape continues evolving, impacting its market share.
Current Market Dynamics
Pricing Trends and Reimbursement
Initially, the wholesale acquisition cost (WAC) for a 100 mg vial of Remdesivir was approximately $520-600 (as per recent reports). Reimbursement rates differ by payers, often influenced by hospital procurement agreements, government contracts, and Medicaid/Medicare policies.[1]
During the peak pandemic phases, pricing was stabilized via government contracts, resulting in temporarily reduced acquisition costs for hospitals. As the market transitions, the drug's price has exhibited gradual increases, correlating with manufacturing scale-downs and market consolidation.
Market Capitalization & Revenue Estimates
Gilead Sciences’ COVID-19 antiviral revenues, predominantly from Remdesivir, surged during 2020-2021, contributing significantly to the company’s growth. However, revenue from Veklury has plateaued or declined slightly as COVID-19 hospitalization rates change and vaccination efforts reduce severe cases.
Price Projections and Future Outlook
Short-Term (1-2 Years)
- Price stabilization is anticipated within the current range ($520–$600 per vial), driven by manufacturing costs, supply chain stability, and hospital procurement practices.
- Reimbursement and policy changes may influence net prices, especially for government-funded programs seeking cost containment.
- Demand fluctuations in COVID-19 hospitalizations will impact volume sales, with potential spikes during surges.
Medium to Long-Term (3-5 Years)
- Market contraction is probable as newer oral antivirals emerge, offering similar efficacy with easier administration.
- Pricing pressure may intensify due to increased generic competition if patent exclusivity terms evolve or if Gilead enters negotiations for voluntary licensing.
- Potential for price erosion exists as the drug transitions from an emergency-use asset to a more niche, indicated therapy.
Regulatory and Policy Influences
Governmental policies, including price controls, strategic stockpiling, and pandemic preparedness measures, will significantly influence prices. Moreover, international markets may adopt different pricing strategies based on local healthcare economics and negotiated procurement contracts.
Market Opportunities and Risks
Opportunities:
- Expansion into emerging markets with increasing COVID-19 case burdens.
- Development of new indications or formulations, potentially boosting market longevity.
Risks:
- Competition from oral antivirals that reduce reliance on IV-administered treatments.
- Regulatory challenges and potential patent expirations.
- Changing clinical guidelines reducing the drug’s relevance in standard care.
Regulatory and Patent Status
Gilead holds patent protections for remdesivir in multiple jurisdictions, with exclusivity expiry ranging between 2023-2026, depending on regional patent laws. Ongoing patent litigation and licensing negotiations could impact future pricing.
Key Takeaways
- The current market for NDC 51407-0486 (Remdesivir) is characterized by stabilization with modest pricing fluctuations.
- Demand dynamics are closely tied to COVID-19 hospitalization trends, with an expectation of gradual decline as newer therapies proliferate.
- Short-term pricing will likely remain within the $520–$600 range per vial, subject to supply chain and reimbursement policies.
- Longer-term projections suggest potential price erosion due to competition, patent expiries, and evolving treatment ecosystems.
- Strategic positioning in expanding markets and ongoing innovation can enhance revenue sustainability.
FAQs
-
What factors influence the current price of remdesivir (Veklury)?
Supply chain costs, manufacturing scale, reimbursement policies, and competitive pressures primarily influence its current pricing.
-
How does patent exclusivity impact remdesivir pricing?
Patent protections prevent generic entry, sustaining higher prices until patents expire or licensing agreements are made.
-
Are there upcoming regulatory changes that could affect remdesivir's market?
Pending patent expirations and evolving treatment guidelines could alter market dynamics, potentially leading to price adjustments or generic competition.
-
What is the outlook for remdesivir in non-COVID viral infections?
Currently limited; future research and clinical trials would be necessary to expand its indications, influencing future market potential.
-
How do government contracts impact remdesivir’s pricing?
Government procurement agreements often result in discounted or stabilized prices during emergencies, impacting overall market pricing.
References
[1] Gilead Sciences Inc. (2022). Veklury Pricing and Reimbursement. Available online.
